Cancer
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
1 April 2019
The WHO Technical Report: Pricing of cancer medicines and its impacts (“the Report”) was published in order to address requests made in a resolution adopted by…
Making Outcome-Based Payment a Reality in the NHS
2 January 2019
This report explores the feasibility of introducing one type of flexible payment mechanism – outcome-based payment (OBP) – for cancer medicines into the NHS in England. OBP could help to accelerate patient access to some new medicines and ensure close monitoring of real-world patient benefit.
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
1 June 2018
Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being…
Extrapolation from Progression-Free Survival to Overall Survival in Oncology
1 December 2016
This Research Paper reports on a literature review of trials using PFS as a surrogate for OS in oncology between 2012 and 2016; a workshop and…
Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
1 December 2016
Published paper using MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to assess the value of obinutuzumab for rituximab-refractory iNHL.
Improving Efficiency and Resource Allocation in Future Cancer Care
9 January 2016
The economic burden that cancer poses on our society is staggering – 25 million years of healthy life lost, at cost of €126 billion including €52…
The Expanding Value Footprint of Oncology Treatments
1 May 2014
This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during 2003–2005. Decisions by France’s HAS, NICE and Aetna in the US are analysed.
Real Option Value and Path Dependence in Oncology Innovation
1 April 2014
Based on an OHE Lunchtime Seminar, this publication addresses a persistent issue: how to adequately reward innovation through the pricing of new medicines given the limitations…
Achieving World Class Outcomes in Cancer Treatment
1 July 2011
The speaker for the OHE’s 16th Annual Lecture was Sir Mike Richards, National Clinical Director for Cancer and End of Life Care in England’s Department of…